К содержанию
РецензированоEN2025

Personalized Approach to The Diagnosis of Neuropathic Pain in Metastatic Breast Cancer: Development of A Multicomponent Questionnaire

PAGE NO. - · Multicomponent Questionnaire · Rakhimov Nodir Makhammatkulovich · Rakhmonov Kamol Aminzhonovich (DSc, Professor, Department of Oncology, Samarkand State Medical University, Samarkand 140100, Uzbekistan) · Shakhanova Shakhnоza Shavkatovna (Independent researcher, Department of Oncology, Samarkand State Medical University, Samarkand 140100, Uzbekistan)

American Journal of Biomedical Science & Pharmaceutical Innovation · 05 · 2025

Аннотация

Objective: To validate the specialized questionnaire "NEURO-RMZh" for the differential diagnosis of neuropathic pain in patients with metastatic breast cancer and to compare its psychometric properties with existing validated instruments. Materials and Methods: A single-center prospective validation study was conducted, enrolling 111 patients with metastatic breast cancer. A comprehensive methodological approach was employed, including assessment of internal consistency, test-retest reliability, construct and criterion validity. Statistical methods included factor analysis, correlation analysis, ROC analysis, and multiple logistic regression. The DN4, BPI, SF-36, and Visual Analogue Scale (VAS) questionnaires were used as comparators. Results: The "NEURO-RMZh" questionnaire demonstrated high internal consistency (Cronbach’s α = 0.89) and test-retest reliability (ICC = 0.94). Its four-factor structure explains 73.6% of the total variance. The diagnostic performance of the questionnaire exceeds that of existing tools: sensitivity 89.7%, specificity 82.4%, area under the ROC curve 0.92. Likelihood ratios (LR+ = 5.10, LR- = 0.13) indicate the clinical significance of the test. Strong correlations were observed with SF-36 quality of life domains (r from -0.44 to -0.74). Conclusion: The "NEURO-RMZh" questionnaire is a valid, reliable, and highly informative tool for the differential diagnosis of neuropathic pain in patients with metastatic breast cancer. Its implementation may contribute to the optimization of diagnostics and personalization of therapeutic strategies in palliative oncology. Keywords: Neuropathic pain, breast cancer, questionnaire, validation, palliative care. Introduction: Breast cancer remains one of the The pathogenesis of pain syndrome in breast cancer is leading causes of cancer morbidity among women characterized by pronounced heterogeneity of worldwide, accounting for 24.5% of all malignant underlying mechanisms. Nociceptive pain is caused by neoplasms in women [1]. Pain syndrome of various the direct effect of the tumor on tissues, inflammatory etiologies develops in 75–90% of patients with processes, and mechanical compression of structures advanced forms of the disease, significantly reducing [4]. Neuropathic pain develops as a result of peripheral quality of life and necessitating a differentiated nerve injury due to tumor progression, neurotoxicity of approach to therapy [2,3]. chemotherapeutic agents (taxanes, platinum American Journal Of Biomedical Science & Pharmaceutical Innovation 38 https://theusajournals.com/index.php/ajbspi American Journal of Applied Science and Technology (ISSN: 2771-2745) compounds, vinca alkaloids), or radiotherapy [5,6]. The assessment of neuropathic pain in patients with breast mixed type of pain, which combines both mechanisms, cancer and to compare its psychometric properties is observed in 39–65% of patients and presents the with existing validated instruments (VAS, DN4, BPI, SF- greatest diagnostic challenges [7]. 36). Current Approaches to Pain Assessment in Oncology METHODS The visual analogue scale (VAS) remains the gold In response to the identified shortcomings of current standard for assessing pain intensity in clinical practice methodologies, we have developed an innovative due to its ease of use and high reproducibility (r=0.94) diagnostic tool that integrates the advantages of [8]. However, the VAS does not allow differentiation of contemporary questionnaires while minimizing their pain types based on pathophysiological mechanisms, limitations. The developed questionnaire comprises 20 limiting its use in selecting targeted therapies for items: 16 for self-completion by the patient and 4 for neuropathic pain [9]. clinical assessment by a specialist. The DN4 is a validated screening tool for neuropathic This diagnostic package is adapted to the specific pain that includes 10 dichotomous questions [10]. DN4 features of neuropathic pain manifestations in demonstrates a sensitivity of 82.9% and a specificity of oncology and is equipped with a detailed data analysis 89.9% at a cut-off value of ≥4 points [11]. Despite its system. This ensures the optimization of diagnostic wide application, the DN4 has significant limitations in procedures and enhances the reliability of differential the oncological population: insufficient validation in diagnosis of various pain types in clinical oncology. patients with chemotherapy-induced polyneuropathy, Such a multicomponent methodology allows for the low specificity for mixed pain types (67.3%), and the most detailed characterization of pain sensations and need for physical examination, which complicates their impact on the patient's daily life. The information telemedicine consultations [12,13]. obtained forms the basis for developing personalized The Brief Pain Inventory (BPI) assesses pain intensity therapeutic programs, which is especially relevant for and its impact on patient functional activity using an

Доказательный фрагмент

«Objective: To validate the specialized questionnaire "NEURO-RMZh" for the differential diagnosis of neuropathic pain in patients with metastatic breast cancer and to compare its psychometric properties with existing v…»

Образец извлечения

Демо-превью

Objective: To validate the specialized questionnaire "NEURO-RMZh" for the differential diagnosis of neuropathic pain in patients with metastatic breast cancer and to compare its psychometric properties with existing v… Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.

Цитирований
0
Просмотров
0
Тип
Журнал
Страна
Узбекистан
Ключевые слова
Neuropathic pain, breast cancer, questionnaire, validation, palliative care
Открыть DOI
Спросить CiteX об этой работе

Смежные источники

[4]МедицинаRUРецензированоОткрытый доступ
BIOGEN ELEMENTLARNING INSON SALOMATLIGIDAGI O’RNI

Медицина, педагогика и технологии: теория и практикаТЕОРИЯ И ПРАКТИКА, Ne’matova F.O. +12024

5